CSM enhances the filtration bleb survival in rabbit model of experimental glaucoma surgery.
OBJECTIVE
The aim of this study is to investigate whether CS-g-MMCs conjugate (CSM) could be a new agent to prevent the post-operative fibrosis in a rabbit model of experimental glaucoma filtration surgery.


METHODS
In a randomized, controlled, masked-observer study, 40 New Zealand White rabbits underwent trabeculectomy in the right eyes and randomly received subconjunctival injection of phosphate buffered saline, chitosan (CS), CSM (100 µg/ml), CSM (200 µg/ml) or Mitomycin C (100 µg/ml). Bleb characteristics and anterior chamber depth were evaluated by slit-lamp examination. The animals were killed on day 14 and 28. Histopathology and immunohistochemistry were performed to determine the amount of the scarring and fibrosis. Ocular toxicity was assessed by histopathology and electron microscope.


RESULTS
We found that the five groups were similar with respect to intraocular pressure and anterior chamber depth. The medians for survival days were: 5.5, 8, 17.5, 28 and 16 in the PBS, CS, CSM100, CSM200 and MMC groups, respectively. Both the CSM200 and the MMC group showed a significantly larger bleb area than the CSM100, CS and the PBS group. Less scarring was seen on day 14 and 28 in CSM200 and MMC group than in the PBS, CS and CSM100 group by histology and immunohistochemistry assessment. No damages were found in the rabbit eyes in each group.


CONCLUSIONS
Subconjunctival injection of CSM postoperatively can improve the filtration bleb survival in the rabbit model. It can be a safe and effective antimetabolite in glaucoma surgery.
Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine , Hangzhou , China .
Jian
J
Ma
Xiaoning
X
Li
Weizhong
W
Zhang
Li
L
Huang
Min
M
Chen
Lei
L
Xi
Zheng
Z
Zhang
Lihong
L
Duan
Daping
D
Quan
Jian
J
Ge
D000477:Alkylating Agents / Q000008:administration & dosage*; D000818:Animals; D048271:Chitosan / Q000008:administration & dosage*; D003228:Conjunctiva / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D004337:Drug Carriers; D005355:Fibrosis / Q000517:prevention & control; D005901:Glaucoma / Q000601:surgery*; D056965:Injections, Intraocular; D007429:Intraocular Pressure; D016685:Mitomycin / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000517:prevention & control; D011817:Rabbits; D014130:Trabeculectomy; D014945:Wound Healing / Q000187:drug effects*
D000477:Alkylating Agents; D004337:Drug Carriers; D016685:Mitomycin; D048271:Chitosan
Antimetabolite; Mitomycin C; chitosan; fibrosis; filtration bleb